Brief Title
A Study to Evaluate the Efficacy and Safety of AD-208
Official Title
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AD-208 in Male Patients With Androgenetic Alopecia
Brief Summary
The purpose of this study is to evaluate the efficacy and safety of AD-208.
Detailed Description
The purpose of this study is to evaluate the efficacy and safety of AD-208 in male patients with androgenetic alopecia.
Study Phase
Phase 3
Study Type
Interventional
Primary Outcome
The amount of Change in the total number of hairs
Condition
Androgenetic Alopecia
Intervention
AD-208
Study Arms / Comparison Groups
Active Comparator
Description: AD-208 and Placebo of AD-2081
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Drug
Estimated Enrollment
130
Start Date
May 31, 2021
Completion Date
April 22, 2022
Primary Completion Date
October 1, 2021
Eligibility Criteria
Inclusion Criteria: - Male patients aged 18-50 years, inclusive - Patients who meet the appropriate criteria according to the classification of hair loss - Signed informed consent Exclusion Criteria: - Patients with hair loss disorders other than androgenetic alopecia - Other exclusions applied
Gender
Male
Ages
18 Years - 50 Years
Accepts Healthy Volunteers
No
Contacts
, +82-031-891-6916, [email protected]
Administrative Informations
NCT ID
NCT04825561
Organization ID
AD-208P3
Responsible Party
Sponsor
Study Sponsor
Addpharma Inc.
Study Sponsor
, ,
Verification Date
March 2021